A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation?

被引:134
作者
Ezzat, Vivienne A. [1 ]
Lee, Victor [1 ]
Ahsan, Syed [1 ]
Chow, Anthony W. [1 ]
Segal, Oliver [1 ]
Rowland, Edward [1 ]
Lowe, Martin D. [1 ]
Lambiase, Pier D. [1 ]
机构
[1] Heart Hosp, London, England
关键词
D O I
10.1136/openhrt-2014-000198
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Implantable cardioverter defibrillator (ICD) implantation carries a significant risk of complications, however published estimates appear inconsistent. We aimed to present a contemporary systematic review using meta-analysis methods of ICD complications in randomised controlled trials (RCTs) and compare it to recent data from the largest international ICD registry, the US National Cardiovascular Data Registry (NCDR). PubMed was searched for any RCTs involving ICD implantation published 1999-2013; 18 were identified for analysis including 6433 patients, mean follow-up 3 months-5.6 years. Exclusion criteria were studies of children, hypertrophic cardiomyopathy, congenital heart disease, resynchronisation therapy and generator changes. Total pooled complication rate from the RCTs (excluding inappropriate shocks) was 9.1%, including displacement 3.1%, pneumothorax 1.1% and haematoma 1.2%. Infection rate was 1.5%. There were no predictors of complications but longer follow-up showed a trend to higher complication rates (p=0.07). In contrast, data from the NCDR ICD, reporting on 356 515 implants (2006-2010) showed a statistically significant threefold lower total major complication rate of 3.08% with lead displacement 1.02%, haematoma 0.86% and pneumothorax 0.44%. The overall ICD complication rate in our meta-analysis is 9.1% over 16 months. The ICD complication reported in the NCDR ICD registry is significantly lower despite a similar population. This may reflect under-reporting of complications in registries. Reporting of ICD complications in RCTs and registries is very variable and there is a need to standardise classification of complications internationally.
引用
收藏
页数:7
相关论文
共 35 条
[1]   Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials [J].
Al-Khatib, Sana M. ;
Hellkamp, Anne ;
Bardy, Gust H. ;
Hammill, Stephen ;
Hall, W. Jackson ;
Mark, Daniel B. ;
Anstrom, Kevin J. ;
Curtis, Jeptha ;
Al-Khalidi, Hussein ;
Curtis, Lesley H. ;
Heidenreich, Paul ;
Peterson, Eric D. ;
Sanders, Gillian ;
Clapp-Channing, Nancy ;
Lee, Kerry L. ;
Moss, Arthur J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (01) :55-62
[2]   Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial [J].
Almendral, Jesus ;
Arribas, Fernando ;
Wolpert, Christian ;
Ricci, Renato ;
Adragao, Pedro ;
Cobo, Erik ;
Navarro, Xavier ;
Quesada, Aurelio .
EUROPACE, 2008, 10 (05) :528-535
[3]   Estimates of Implantable Cardioverter-Defibrillator Complications Caveat Emptor [J].
Anderson, Kelley P. .
CIRCULATION, 2009, 119 (08) :1069-1071
[4]   The quick-implantable-defibrillator trial [J].
Baensch, Dietmar ;
Kottkamp, Hans ;
Groenefeld, Gerian ;
Vogt, Juergen ;
Israel, Carsten ;
Boecker, Dirk ;
Hindricks, Gerd ;
Kuck, Karl-Heinz .
EUROPACE, 2007, 9 (12) :1144-1150
[5]   Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy -: The cardiomyopathy trial (CAT) [J].
Bänsch, D ;
Antz, M ;
Boczor, S ;
Volkmer, M ;
Tebbenjohanns, J ;
Seidl, K ;
Block, M ;
Gietzen, F ;
Berger, J ;
Kuck, KH .
CIRCULATION, 2002, 105 (12) :1453-1458
[6]   The 1+1 trial -: A prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias [J].
Bänsch, D ;
Steffgen, F ;
Grönefeld, G ;
Wolpert, C ;
Böcker, D ;
Mletzko, RU ;
Schöls, W ;
Seidl, K ;
Piel, M ;
Ouyang, F ;
Hohnloser, SH ;
Kuck, KH .
CIRCULATION, 2004, 110 (09) :1022-1029
[7]   Long-term comparison of the implantable cardioverter defibrillator versus amiodarone - Eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS) [J].
Bokhari, F ;
Newman, D ;
Greene, M ;
Korley, V ;
Mangat, I ;
Dorian, P .
CIRCULATION, 2004, 110 (02) :112-116
[8]  
Bonow RO, 2008, J AM COLL CARDIOL, V52, pE1, DOI [10.1016/j.jacc.2008.02.032, 10.1016/j.hrthm.2008.04.014, 10.1016/j.jacc.2008.05.007]
[9]   Are complications of implantable defibrillators under-estimated and benefits over-estimated? [J].
Brignole, Michele .
EUROPACE, 2009, 11 (09) :1129-1133
[10]   Implantable cardioverter-defibrillator lead failure: how weak is the link? [J].
Brinker, Jeffrey A. .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (12) :758-759